N
TVTX icon

Nuveen’s Travere Therapeutics TVTX Stock Holding History

Nuveen’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.9M Sell
938,569
-55,044
-6% -$1.65M 0.01% 947
2025
Q4 		$38M Sell
993,613
-85,078
-8% -$2.77M 0.01% 782
2025
Q3 		$25.8M Sell
1,078,691
-115,644
-10% -$2.17M 0.01% 988
2025
Q2 		$17.7M Sell
1,194,335
-9,309
-0.8% -$154K ﹤0.01% 1180
2025
Q1 		$21.6M Sell
1,203,644
-539,546
-31% -$11M 0.01% 1086
2024
Q4 		$30.4M Sell
1,743,190
-88,913
-5% -$1.57M 0.01% 908
2024
Q3 		$25.6M Buy
1,832,103
+1,094,465
+148% +$11.4M 0.01% 1020
2024
Q2 		$6.06M Buy
737,638
+6,260
+0.9% +$42.2K ﹤0.01% 1848
2024
Q1 		$5.64M Buy
731,378
+247,050
+51% +$2.08M ﹤0.01% 1928
2023
Q4 		$4.35M Sell
484,328
-220,975
-31% -$1.61M ﹤0.01% 2059
2023
Q3 		$6.31M Sell
705,303
-185,474
-21% -$2.62M ﹤0.01% 1748
2023
Q2 		$13.7M Buy
890,777
+563,124
+172% +$10.2M ﹤0.01% 1315
2023
Q1 		$7.37M Buy
327,653
+143,585
+78% +$3.05M ﹤0.01% 1662
2022
Q4 		$4.54M Sell
184,068
-225,420
-55% -$4.78M ﹤0.01% 1968
2022
Q3 		$10.1M Sell
409,488
-27,469
-6% -$710K ﹤0.01% 1467
2022
Q2 		$10.8M Buy
436,957
+28,988
+7% +$729K ﹤0.01% 1453
2022
Q1 		$10.1M Sell
407,969
-9,855
-2% -$262K ﹤0.01% 1634
2021
Q4 		$10.3M Sell
417,824
-58,721
-12% -$1.65M ﹤0.01% 1671
2021
Q3 		$11.8M Sell
476,545
-196,772
-29% -$3.62M ﹤0.01% 1667
2021
Q2 		$16.6M Sell
673,317
-193,909
-22% -$3.82M ﹤0.01% 1512
2021
Q1 		$21.4M Buy
867,226
+106,204
+14% +$2.93M 0.01% 1268
2020
Q4 		$18.8M Buy
761,022
+44,871
+6% +$1.05M 0.01% 1304
2020
Q3 		$13.2M Buy
716,151
+120,618
+20% +$2.34M 0.01% 1333
2020
Q2 		$12.2M Buy
595,533
+34,000
+6% +$541K ﹤0.01% 1356
2020
Q1 		$8.19M Buy
561,533
+4,547
+0.8% +$68.4K ﹤0.01% 1418
2019
Q4 		$7.91M Sell
556,986
-16,089
-3% -$206K ﹤0.01% 1730
2019
Q3 		$6.64M Sell
573,075
-137,386
-19% -$2.27M ﹤0.01% 1803
2019
Q2 		$14.3M Buy
+710,461
New +$14M 0.01% 1378

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's TVTX Position: Q1 2026 in Review

Nuveen reduced its Travere Therapeutics (TVTX) stake by 5.5% in Q1 2026, selling an estimated $1.65M and leaving 938,569 shares worth $27.9M. The position accounts for 0.01% of the portfolio, ranked #947.

Nuveen first reported a position in TVTX in Q2 2019 and has held it in 28 quarters since. The position peaked at $38M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Nuveen held 938,569 shares of Travere Therapeutics worth $27.9M as of Q1 2026.
  • Nuveen sold 55,044 Travere Therapeutics shares in Q1 2026, an estimated $1.65M.
  • Travere Therapeutics made up 0.01% of Nuveen's portfolio in Q1 2026, its #947 holding.
  • Nuveen first reported a position in Travere Therapeutics in Q2 2019 and has held it in 28 quarters since.
  • Nuveen's Travere Therapeutics position peaked at $38M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.